α-ketoheterocycles as inhibitors of Leishmania mexicana cysteine protease CPB.
Cysteine proteases of the papain superfamily are present in nearly all eukaryotes and also play pivotal roles in the biology of parasites. Inhibition of cysteine proteases is emerging as an important strategy to combat parasitic diseases such as sleeping sickness, Chagas disease, and leishmaniasis. Inspired by the in vivo antiparasitic activity of the vinylsulfone-based cysteine protease inhibitors, a series of α-ketoheterocycles were developed as reversible inhibitors of a recombinant L. mexicana cysteine protease, CPB2.8. Three isoxazoles and especially one oxadiazole compound are potent reversible inhibitors of CPB2.8; however, in vitro whole-organism screening against a panel of protozoan parasites did not fully correlate with the observed inhibition of the cysteine protease.
Steert
Koen
K
Department of Medicinal Chemistry, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium.
Berg
Maya
M
Mottram
Jeremy C
JC
Westrop
Gareth D
GD
Coombs
Graham H
GH
Cos
Paul
P
Maes
Louis
L
Joossens
Jurgen
J
Van der Veken
Pieter
P
Haemers
Achiel
A
Augustyns
Koen
K
D000981:Antiprotozoal Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D002460:Cell Line; D057056:Cysteine Proteases / Q000737:chemistry* / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D006571:Heterocyclic Compounds / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D018314:Leishmania infantum / Q000187:drug effects; D007894:Leishmania mexicana / Q000201:enzymology*; D010963:Plasmodium falciparum / Q000187:drug effects; D014346:Trypanosoma brucei brucei / Q000187:drug effects; D014349:Trypanosoma cruzi / Q000187:drug effects
D000981:Antiprotozoal Agents; D015853:Cysteine Proteinase Inhibitors; D006571:Heterocyclic Compounds; D057056:Cysteine Proteases
Chem Rev. 2002 Dec;102(12):4459-88
12475197
J Med Chem. 1994 Oct 14;37(21):3492-502
7932578
Bioorg Med Chem. 2003 Jan 2;11(1):21-9
12467703
J Ethnopharmacol. 2006 Jul 19;106(3):290-302
16698208
Comp Biochem Physiol B. 1986;83(3):629-32
3956174
Bioorg Med Chem Lett. 2010 Mar 15;20(6):2001-6
20167486
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6008-13
8650210
Biochem J. 1972 Aug;129(1):197-202
4630451
Mol Microbiol. 2006 Aug;61(3):655-74
16803590
Infect Immun. 2009 Jul;77(7):2971-8
19433541
J Org Chem. 2007 Jul 20;72(15):5828-31
17585818
Bioorg Med Chem Lett. 2005 Sep 1;15(17):3891-5
15993587
J Immunol. 2003 Feb 15;170(4):1746-53
12574338
Bioorg Med Chem. 2005 Mar 15;13(6):2141-56
15727867
J Med Chem. 2002 Dec 5;45(25):5471-82
12459015
Bioorg Med Chem Lett. 2007 Aug 1;17(15):4167-72
17544668
J Biol Chem. 2001 Dec 14;276(50):47061-9
11592967
Exp Parasitol. 2004 Mar-Apr;106(3-4):158-63
15172223
J Med Chem. 2005 Mar 24;48(6):1984-2008
15771442
J Exp Med. 1998 Aug 17;188(4):725-34
9705954
Antimicrob Agents Chemother. 2005 Dec;49(12):5160-1
16304193
Exp Parasitol. 1999 Apr;91(4):349-55
10092479
J Immunol. 1998 Dec 15;161(12):6794-801
9862710
J Med Chem. 2004 Dec 16;47(26):6609-15
15588096
Bioorg Med Chem Lett. 2006 Jun 1;16(11):2909-14
16546382
Bioorg Med Chem Lett. 2007 Dec 1;17(23):6563-6
17936625
J Org Chem. 2003 Feb 21;68(4):1418-25
12585882
Mol Biochem Parasitol. 2002 Mar;120(1):1-21
11849701
Bioorg Med Chem. 2008 Feb 15;16(4):1562-95
18053726
Exp Parasitol. 1999 Apr;91(4):327-33
10092476
Curr Opin Infect Dis. 2008 Dec;21(6):668-72
18978536
Methods Enzymol. 1979;63:437-67
502865
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11015-22
10500116
Parasitology. 2000 Oct;121 ( Pt 4):367-77
11072899
Biochem J. 2000 Apr 15;347(Pt 2):383-8
10749667
Int J Parasitol. 2007 Aug;37(10):1063-75
17493624
Infect Immun. 2003 Jun;71(6):3190-5
12761098